ISR Immune System Regulation Holding AB (publ) Stock

ISR

SE0008212195

Biotechnology & Medical Research

Latest news : ISR Immune System Regulation Holding AB (publ)

23-08-28	Immune System Regulation AB Announces Sars-Cov-2 Dry Powder Nasal - Vaccine Booster Candidate, Isr52, Demonstrates Superior Immune Response, in Mouse Model Challenge Studies Compared to Subcutaneous injection of this vaccine	CI
23-05-24	ISR delisted from First North with immediate effect	FW
23-05-24	ISR delisted by Nasdaq's disciplinary committee	FW
23-03-31	25 companies in the obs class on Nasdaq Stockholm and First North	FW
23-03-08	ISR risks delisting	FW
23-02-28	ISR Immune System Regulation Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-12-30	Creditors file for bankruptcy of trade-stopped ISR	FW
22-08-31	ISR Immune System Regulation Holding AB Reports Earnings Results for the Half Year Ended June 30, 2022	CI
22-07-01	ISR Receives Approval To Conduct Clinical Trial In Bangladesh	MT
22-07-01	ISR’s Immune System Regulation Holding AB Announces Sars-Cov-2 Vaccine Study Approved by Bangladesh Bmrc	CI
22-06-28	ISR Immune System Regulation Holding AB Signs Development Agreements with Catalent to Scale-Up Its Spray-Dried Nasal Vaccine, Powder Formulation for Phase III	CI
22-02-23	ISR Immune System Regulation Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	CI
22-02-23	ISR Immune System Regulation Holding AB Reports Earnings Results for the Full Year Ended December 31, 2021	CI

More news

Analysts' recommendations : ISR Immune System Regulation Holding AB (publ)

23-03-31

25 companies in the obs class on Nasdaq Stockholm and First North

More recommendations

Press Releases : ISR Immune System Regulation Holding AB (publ)

22-07-01	SARS-CoV-2 vaccine study approved by Bangladesh BMRC	AQ
22-06-28	ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.	AQ
22-06-20	Delegation from Bangladesh visits ISR for study preparation	AQ
22-06-14	ISR Immune System Regulation : Holding Annual Report and Consolidated Accounts 2021 (eng) (PDF)	PU
22-05-05	Redeye Initiates Coverage of ISR Holding	AQ

More press releases

Managers and Directors : ISR Immune System Regulation Holding AB (publ)

Manager	Title	Age	Since
Ola Winqvist CEO	Chief Executive Officer	61	2017-12-31
Jonas Winqvist DFI	Director of Finance/CFO	57	2020-12-31
Johan Sjodahl CTO	Chief Tech/Sci/R&D Officer	54	2020-12-31

Director	Title	Age	Since
Anders Harald Milton CHM	Chairman	78	2015-12-31
Jan Erik Gunnar Jardelöv BRD	Director/Board Member	79	2015-09-16
Richard Bergström BRD	Director/Board Member	-	2021-12-31

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)	-.--%	-43.37%	-	-	9.92M
LONZA GROUP AG	-0.71%	-6.35%	-2.99%	+9.59%	45.48B
REVOLUTION MEDICINES, INC.	+0.21%	-2.98%	+337.74%	+519.55%	43.68B
IQVIA HOLDINGS INC.	+1.74%	-2.24%	+39.82%	+20.76%	43.09B
BEONE MEDICINES AG	+1.38%	-3.28%	+6.84%	+67.62%	39.4B
CELLTRION, INC.	-1.44%	-5.26%	+8.97%	+39.76%	31.91B
ASCENDIS PHARMA A/S	+0.87%	-2.60%	-	-	17.31B
MEDPACE HOLDINGS, INC.	+0.75%	-0.64%	+19.75%	+110.17%	16.4B
EUROFINS SCIENTIFIC SE	-0.31%	-2.78%	+10.78%	+31.02%	14.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.93%	-3.55%	+82.00%	+41.17%	13.28B
Average	+0.44%	-3.57%	+62.86%	+104.96%	29.42B
Weighted average by Cap.	+0.41%	-3.67%	+74.57%	+124.26%

See all sector performances

ISR Immune System Regulation Holding AB (publ) is a Sweden-based research company within the area of immunotherapy. The Company is focused the development of drug therapies for viral infections, in particular human immunodeficiency virus (HIV). The Company's product candidate, ISR048, is undergoing phase II of clinical trials for HIV indications. It provides a resistance profile, which does not require co-dosing with a boosting agent. A second generation anti-HIV drug candidate, ISR049, is in preclinical development. The Company's another drug candidate in development, ISR050, shows immunostimulatory properties that are being explored in vitro and in animal models of chronic infections, such as tuberculosis.

Employees

Sector

Biotechnology & Medical Research

More about the company